Given the central role for the tyrosine kinase Syk in FcεRI-mediated signaling, we evaluated whether pharmacologic inhibition of Syk using the potent and selective small molecule inhibitor PRT062607 (Coffey et al., 2017; Spurgeon et al., 2013) could ameliorate development of murine osteoarthritis. The gene discussed is FCER1A; the disease is osteoarthritis.